Product Description
Emedastine is a second generation, selective histamine H1 receptor antagonist with anti-allergic activity. Emedastine reversibly and competitively blocks histamine by binding to H1 receptors, thus blocking its downstream activity. As a result this agent interferes with mediator release from mast cells either by inhibiting calcium ion influx across mast cell/basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Emedastine)
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Malaysia | Morocco | Netherlands | Norway | Pakistan | Philippines | Poland | Portugal | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Hisamitsu
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Japan
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Conjunctivitis, Allergic|Rhinitis, Allergic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-515717-17-00 |
T502-SIT-073 | P3 |
Active, not recruiting |
Rhinitis, Allergic|Conjunctivitis, Allergic |
2025-06-13 |
2025-05-02 |
Treatments |
|
JapicCTI-183844 |
JapicCTI-183844 | P2 |
Active |
Rhinitis, Allergic |
None |